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Re-Expression of the Retinoblastoma-Binding Protein
2-Homolog 1 Reveals Tumor-Suppressive Functions
in Highly Metastatic Melanoma Cells
Alexander Roesch1, Bernd Becker1, Wulf Schneider-Brachert2, Ilja Hagen3, Michael Landthaler1 and
Thomas Vogt1
The loss of cell cycle control in malignant melanomas is thought to be due to a lack of retinoblastoma protein
(pRb) activity. We have recently reported a progressive deficiency of the retinoblastoma-binding protein
2-homolog 1 (RBP2-H1) in advanced and metastatic melanomas in vivo, suggesting a role of RBP2-H1 in loss of
pRb-mediated control. Therefore, in this study, we re-established the pRb-modulating function of RBP2-H1 in
highly metastatic A375-SM melanoma cells by re-expressing its C-term (cRBP2-H1). As previously shown, the
corresponding domains comprise the pRb-binding region of the RBP2-H1 protein (non-T/E1A-pRb-binding
domain (NTE1A)). As a result, we detected pRb-hypophosphorylation selectively at Ser795, but not at Ser780 and
Ser807/811 throughout the G1 phase of the cell cycle. As a further consequence, a block in G1/S transition was
observed accompanied by a significant decrease of DNA replication and cellular proliferation. As demonstrated
by cDNA microarrays of cRBP2-H1-transduced cells and confirmed by quantitative TaqManTM reverse
transcriptase-PCR, differential expression of melanoma-progression-related genes was observed, among them
bone morphogenetic protein 2, follistatin, transforming growth factor alpha, hepatocyte growth factor,
transcription factor 4 and microphthalmia-associated transcription factor. Conclusively, these data suggest
that RBP2-H1 exerts a broad tumor-suppressive function partially mediated by pRb modulation. Therefore,
re-establishing of RBP2-H1 could evolve as an interesting novel approach in developing experimental
treatments for metastatic melanomas.
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INTRODUCTION
During G1/S transition, the antiproliferative function of
active, hypophosphorylated retinoblastoma protein (pRb) is
mediated by binding to pro-proliferative transcription factors
such as E2F, c-Myc, ATF-2, PU.1, and c-Abl (Kaelin, 1997,
1999; Taya, 1997). Accordingly, loss of pRb or mutations are
the hallmarks of some human cancers, such as small-cell lung
cancer or retinoblastoma. Paradoxically in malignant mela-
noma, wild-type pRb is overexpressed (Saenz-Santamaria
et al., 1995; Maelandsmo et al., 1996), but, at the same
time, as we could show recently, there is a prognostically
relevant increase of pRb hyperphosphorylation/inactivation
in advanced and metastatic malignant melanomas (Roesch
et al., 2005a).
Persistent hyperphosphorylation of wild-type pRb in
melanomas can be partly attributed to a sustained cyclin-
dependent kinase activity (cdk2, cdk4, and cdk6), for
example due to genetic alterations eliminating the activity
of cyclin-dependent kinase inhibitor such as p16/INK4a,
reviewed by Halaban (1999), Halaban et al. (2000), and
Czajkowski et al. (2002). Deficiency of p16, the best studied
cyclin-dependent kinase inhibitor in melanomas, contributes
to inherited malignant melanoma (5–10% of all cases), but
in sporadic melanomas (about 95% of all cases) the role
of p16 is still controversial, because some of the studies
have revealed p16 deficiency only in a minority of the cases
studied (Kumar et al., 1998; Wagner et al., 1998). Hence,
such deficiency of the tumor-suppressive action of p16 is an
important event in a certain subset of melanomas. However,
the full spectrum of possible mechanisms undermining the
function of pRb still remains to be established.
As we could also recently demonstrate, there is a progressive
loss of a further potential pRb-modulator in melanomas termed
RBP2-homolog 1 (retinoblastoma-binding protein 2-homolog 1
(RBP2-H1)). RBP2-H1 expression is downregulated in the
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majority of advanced and metastatic melanomas in vivo,
whereas benign melanocytic nevi are mostly RBP2-H1 posi-
tive (Roesch et al., 2005b). RBP-2 (alternatively RBBP2,
RBP2) itself was originally found by Defeo-Jones et al. (1991)
by exploiting its binding to pRb. Its close homolog, RBP2-H1,
was detected by our group due to its abundant expression and
its UV-B responsiveness in normal human melanocytes (Acc.
No. AF087481, Vogt et al., 1999). Computerized sequence
analyses of RBP2-H1 had revealed various highly conserved
motifs, among them a domain that is mediating direct binding
and interaction with pRb (non-T/E1A-pRb binding domain
(NTE1A)). By co-immunoprecipitation and Western blot
analyses in RBP2-H1-expressing cell lines, such as IGR-1
melanoma or MCF-7 breast carcinoma cells, we could
confirm that endogenously expressed RBP2-H1 can bind
to pRb which underscores a true pRb-interacting activity of
RBP2-H1 protein (Roesch et al., 2005b).
In this study, we collect evidence that the presence of
RBP2-H1 modulates pRb phosphorylation status and that its
re-expression in RBP2-H1-deficient melanoma cells can both
suppress growth and induce differential expression of a broad
spectrum of melanoma-progression-related genes.
RESULTS
Re-expression of cRBP2-H1 in melanoma cells
The C-term of RBP2-H1 (cRBP2-H1) containing the NTE1A
domain (amino acid (aa) 1391–1490) was subcloned into a
lentiviral expression vector finally coding for a FLAG-tagged
cRBP2-H1 fusion protein (Figure 1). After stable infection of
A375-SM cells with the lentiviral construct, exclusively in
transduced cells the presumed band of 22.58 kDa could be
detected by the specific anti-FLAG antibody (Figure 2). A375-
SM melanoma cells were used for the re-expression because
of their previously reported lack of endogenous RBP2-H1
expression (Roesch et al., 2005b).
Re-expressed cRBP2-H1 binds to pRb
Consistent with previous results showing pRb binding of
endogenously expressed RBP2-H1 in RBP2-H1-expressing
cell lines (Roesch et al., 2005b), co-immunoprecipitation
of pRb with re-expressed cRBP2-H1 and, vice versa, the co-
immunoprecipitation of cRBP2-H1 with pRb demonstrate
binding of the expressed C-term to pRb (Figure 3). Green
fluoroscent protein (GFP)-transduced control cells as well as
non-infected A375-SM failed to show any co-precipitation.
Re-expression of cRBP2-H1 stabilizes hypophosphorylation
at pRb Ser795, but not Ser780 and Ser807/811
Ser780, Ser807/811, and Ser795 are selected phosphoaccep-
tor sites which we reported to be differentially phosphory-
lated during melanoma progression (Roesch et al., 2005a). In
addition, they represent different cdk/cyclin targets. Ser795 is
a substrate of cdk4/cyclin D and cdk2/cyclin E, whereas
Ser780 and Ser807/811 represent exclusively cdk4-targeted
phosphoacceptor sites. Cdk4,6/cyclin D-mediated phosphory-
lation of pRb in early G1 is a prerequisite for the transition of
unphosphorylated, non-functional pRb into hypophosphory-
lated, active pRb, whereas cdk2/cyclin E-mediated hyper-
phosphorylation, for example of Ser795, leads to pRb
inactivation in late G1 with subsequent G1/S transition and
uncontrolled growth in melanomas and other cancers
(Connell-Crowley et al., 1997; Ezhevsky et al., 1997; Kaelin,
1997, 1999; Brown et al., 1999).
For rapidly replicating human cells with an average total
cycling time of 24 hours, the G1 phase is reported to last
about 9 hours (Lodish et al., 2000; Cooper, 2003). Therefore,
to compare early cdk4/cyclin D- and late cdk2/cyclin E-medi-
ated pRb phosphorylation in G1, we stopped cell growth 3 or
9 hours after release from colchicine treatment, respectively.
aa1385 aa1580C-term of RBP2-H1
1391 1490 FLAG
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NonT/E1A-pRb-
binding domain
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M DYKDE
Figure 1. Lentiviral construct. The C-term of RBP2-H1 containing the NTE1A
of RBP2-H1 (aa 1391–1490) and a LMO2-binding domain (aa 1536–1574)
was subcloned into the lentiviral expression vector pQCXIP finally coding
for a FLAG-tagged cRBP2-H1 fusion protein.
kDa kDaA3
75
-SM
cR
BP
2-H
1
GF
P c
on
tro
l vi
rus
Co
ntr
ol
Anti-FLAG
FL
AG
-BA
P
TM
Anti-FLAG
Anti-PDI
25
15
75
50
50
35
Figure 2. Lentiviral re-expression of cRBP2-H1. In contrast to uninfected
A375-SM melanoma cells and cells infected with a lentiviral construct coding
for GFP, exclusively in cRBP2-H1-transduced cells the specific
anti-FLAG antibody could detect the presumed band of 22.58 kDa. 20 ng
of FLAG-BAP
TM
fusion protein served as antibody control. PDI was used as
loading control.
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Figure 3. Co-immunoprecipitation of pRb with cRBP2-H1. In contrast to
uninfected A375-SM melanoma cells and cells infected with the GFP control,
exclusively in cRBP2-H1-transduced cells a co-immunoprecipitation of pRb
with expressed cRBP2-H1 was seen. Co-immunoprecipitation succeeded in
both directions, that is precipitation with anti-FLAG and detection with anti-
pRb antibody (upper row) or precipitation with anti-pRb and detection with
anti-FLAG antibody (lower row). Unspecific signals larger in size than the
fusion peptide are marked with an asterisk. They fail to show any co-
immunoprecipitation.
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According to the reported cdk2/cyclin E-mediated increase of
Ser795 phosphorylation in late G1, in untreated A375-SM
and control virus-infected cells, a weak increase of Ser795
phosphorylation was observed 9 hours after synchronization
also in our experiments (Figure 4a). But, most interestingly, in
cRBP2-H1-re-expressing cells, a significant hypophosphory-
lation was found specifically at Ser795, independent of
harvesting cells in early or late G1 phase. At pRb Ser780 and
Ser807/811 no change in phosphorylation could be seen in
cRBP2-H1-transduced A375-SM cells compared to native
A375-SM cells and cells infected with the control virus. As a
further control, cells transfected with a construct lacking the
NTE1A domain failed to stabilize the hypophosphorylation at
each of the analyzed phospho-sites (Figure 4b).
Furthermore, possible influences on pRb phosphorylation
in cRBP2-H1-transduced cells due to possibly altered protein
levels of cdk4 and cyclinD1 were excluded by immunoblot-
ting (Figure 5). In accordance to the mRNA expression data
recorded in our microarray experiments (see below), cdk4
and cyclinD1 did not show differential regulation upon
cRBP2-H1 transduction. cdk4 microarray calls were 1,097,
1,175, and 1,236, cyclinD1 calls were 194, 118, and 321 in
untreated A375-SM, control virus-infected, and cRBP2-H1-
transduced cells, respectively. p16 expression was comple-
tely absent on mRNA and protein level (not shown). Total
pRb as well as protein disulfide isomerase (PDI) expression
remained unchanged in all samples.
Re-expression of cRBP2-H1 favors G1 arrest and inhibits
cellular proliferation in highly metastatic melanoma cells
In accordance to the detected stabilization of hypophos-
phorylated pRb Ser795, after cRBP2-H1-re-expression, we
found a striking shift within the G1, S, G2/M phases of the
cell cycle profile in our FACS analysis (Figure 6a). Consistent
with a G1 arrest, in cRBP2-H1-transduced A375-SM cells,
there is a highly significant increase in the G1 portion of the
cell cycle profile (44.93% of all cells) compared to 15.42% of
untreated or 25.16% of control virus-infected A375-SM cells.
Table 1 gives the mean values and standard deviations of
six independently performed experiments. As a consequence
of the observed G1 arrest, cRBP2-H1-transduced cells exhibit
a significantly reduced BrdU incorporation during the S
phase (Po0.03, Figure 6b). Notably, the cell cycle profiles as
well as the incorporated amounts of BrdU were congruent in
non-infected A375-SM and control virus cells, respectively.
In accordance with the observed G1 arrest and the reduc-
tion of S-phase DNA replication, in fluorometric proliferation
assays, we also found a significant reduction of cellular
proliferation of A375-SM cells after cRBP2-H1 re-expression
using alamarBlueTM staining (Figure 7).
Re-expression of cRBP2-H1 in metastatic melanoma cells
influences the transcriptional response of melanoma-relevant
genes
GeneChipTM microarray assays (AffymetrixTM, Santa Clara, CA)
were performed as duplicates for comparative gene expres-
sion analysis of cRBP2-H1-re-expressing A375-SM cells
versus control virus-infected and untreated A375-SM cells.
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Figure 4. Phospho-pRb immunoblot. (a) In lentivirus-transduced A375-SM cells selectively re-expressing cRBP2-H1, a stabilizing potential on hypopho-
sphorylated Ser795 was detected 3 and 9 hours after release from colchicine synchronization. Phosphorylation was compared to untreated A375-SM cells and
cells infected with a control virus coding for a non-cell-cycle-related protein (GFP). At Ser780 and Ser807/811, no change in pRb phosphorylation was observed.
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N-term of RBP2-H1 lacking the NTE1A fails to stabilize hypophosphorylated pRb at each of the analyzed phospho-sites. No differences could be seen compared
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kDa
47.5
32.5
25
kDa
47.5
47.5
32.5
25
62
47.5
62
AnticyclinD1 Anticdk4
Anti-PDIAnti-PDI
A3
75
-SM
Co
ntr
ol v
iru
s
cR
BP
2-H
1
A3
75
-SM
Co
ntr
ol v
iru
s
cR
BP
2-H
1
Figure 5. Control immunoblot. CyclinD1 and cdk4 protein expression levels
remained unchanged between cRBP2-H1-transduced cells, untreated
A375-SM cells, and cells infected with the control virus. PDI expression
also remained constant.
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After stringent data filtering (see Materials and Methods), out
of 47,000 genes spotted on the U133A 2.0 GeneChipTM, 340
spots remained differentially regulated (supplementary text).
Among the regulated transcripts, particularly cancer-related
genes affecting cellular growth and differentiation, cell death,
tissue development as well as tumor morphology could be
functionally grouped by the IngenuityTM Pathways Analysis
software based on common published experimental data
(Raponi et al., 2004) (Table 2). Of note, the IngenuityTM
software algorithm found 22.6% (77 genes) of all differen-
tially regulated genes to be linked to cellular growth and
proliferation pathways. Remaining genes, which were not
grouped into tumorigenesis-related global pathways, were
either linked to non-tumorigenesis-related pathways, such
as carbohydrate metabolism, or could not be significantly
assorted at all.
Applying the IngenuityTM network algorithm, 11 functional
networks could be constituted in total. Each of them con-
tained more than 10 regulated focus genes with significant
Ingenuity scores (Raponi et al., 2004) of 9 and more. Among
all networks, two reached particularly high IngenuityTM scores
(network 1 score: 23, network 2 score: 12). Strikingly,
both networks also comprised genes highly relevant for
melanocytic biology, for example microphthalmia-associated
transcription factor (MITF, downregulated), dopachrome
tautomerase (downregulated), tyrosinase-related protein 1
(downregulated), transcription factor 4 (TCF4 upregulated) or
hepatocyte growth factor (HGF, downregulated). By addi-
tional literature search, both networks could be linked using
SPI1 (spleen focus forming virus proviral integration onco-
gene spi1, PU.1, Tcfpu.1) as a branching point (Figure 8).
Consistent with pRb-mediated effects, there were examples of
typical E2F-dependent genes among the regulated genes that
are also melanoma relevant, for example follistatin (down-
regulated), bone morphogenetic protein 2 (upregulated) and
transforming growth factor alpha (downregulated) (Bracken
et al., 2004).
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Figure 6. Cell cycle analysis. (a) Cell cycle profiling with propidium iodide
(FACS).In contrast to native A375-SM cells (dark blue) and control
virus-infected cells (black), cRBP2-H1-transduced A375-SM cells (light blue)
show a highly significant shift from S- and G2/M phase towards G1 phase
(G1 arrest). The cell cycle profiles of non-infected A375-SM and control virus
cells were almost congruent. Depicted is the result of one representative
experiment out of six independently performed experiments. (b) BrdU
incorporation into replicated DNA (Cell Proliferation ELISA
TM
). As a
consequence of the observed G1 arrest, cRBP2-H1-transduced cells exhibit
significantly reduced BrdU incorporation during the S phase compared to
both controls.
Table 1. Cell cycle profile of untreated A375-SM cells,
GFP control virus infected, and cRBP2-H1-re-expres-
sing A375-SM cells (mean values of six independent
experiments)
Cell cycle phase
G1 S G2/M
Mean SD Mean SD Mean SD
Untreated A375-SM (%) 15.42 1.32 17.55 1.00 38.77 3.95
Control virus-transduced
A375-SM (%)
25.16 3.01 21.59 2.64 38.00 1.45
cRBP2-H1-transduced
A375-SM (%)
44.93 1.15 16.26 1.35 29.40 1.17
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Figure 7. AlamarBlue
TM
fluorescence assay. Compared to native A375-SM
cells and control virus-infected cells, cRBP2-H1-re-expressing A375-SM cells
show a highly significant reduction in cellular proliferation, probably due to
G1 arrest.
Table 2. In cRBP2-H1-re-expressing A375-SM cells,
differentially regulated transcripts are involved in
global tumorigenesis-relevant functions and pathways
Global function
No. of involved
genes
Percentage referred to
all regulated genes
Cellular growth and
proliferation
77 22.6
Cancer 77 22.6
Cell death 75 22.1
Tissue development 59 17.4
Cellular movement 54 15.9
Tissue morphology 49 14.4
Tumor morphology 27 7.9
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For validation of the microarray experiments, six melano-
ma-relevant genes (three upregulated and three downregu-
lated genes) were selected and differential regulation of all
selected genes could all be confirmed by TaqManTM real-time
reverse transcriptase-PCR (Table 3).
DISCUSSION
We have recently reported a progressive loss of RBP2-H1 in
advanced melanocytic tumors (Roesch et al., 2005b). RBP2-
H1 directly binds and possibly interacts with pRb mediated
by its NTE1A (Vogt et al., 1999; Roesch et al., 2005b). In the
present study, we re-established partial functions of RBP2-H1
in melanoma cells by lentiviral transduction of the C-term of
RBP2-H1 comprising the NTE1A domain. For the first time,
we provide evidence that re-expressed cRBP2-H1 exerts a
growth and tumor suppressive profile in melanoma cells
which may partly be due to a direct modulation of pRb
phosphorylation and function.
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Figure 8. cRBP2-H1-induced gene regulation. Combining Ingenuity
TM
network analysis with conventional literature research, two networks including
melanoma-relevant genes, as for example MITF, dopachrome tautomerase, tyrosinase-related protein 1, TCF4, or HGF (hepatocyte growth factor) could be
linked using SPI1 (spleen focus forming virus proviral integration oncogene spi1, PU.1, Tcfpu.1) as a branching point. Moreover, screening the list of filtered
genes manually, also typically E2F-regulated genes, as for example follistatin (follistatin), bone morphogenetic protein 2 (BHP-2), and transforming growth factor
alpha were found to be regulated. White symbols: no regulation found, green: downregulation, red: upregulation. The depicted value represents the regulation
cRBP2-H1/NTE1A versus GFP control. A: activation, B: binding, E: expression.
Table 3. TaqManTM real-time RT-PCR confirmation of six melanoma-relevant genes
GeneChipTM microarray assay TaqManTM real-time RT-PCR
Gene name
Gene
symbol
cRBP2-H1-re-expressing
versus control
virus-infected
A375-SM (fold change)
cRBP2-H1-re-expressing
versus uninfected
A375-SM (fold change)
cRBP2-H1-re-expressing
versus control
virus-infected
A375-SM (fold change)
cRBP2-H1-re-expressing
versus uninfected
A375-SM (fold change)
Membrane metallo-
endopeptidase
MME 28.41 14.43 11.04 2.91
Endothelin 1 EDN1 25.74 21.00 120.23 1790.36
Transcription factor 4 TCF4 24.82 52.68 32.77 488.59
Dopachrome tautomerase DCT 34.15 16.9 452.43 332.75
Hyaluronan and
proteoglycan link protein 1
HAPLN1 53.65 163.92 11.97 45.59
Hepatocyte growth factor HGF 76.61 28.00 25.37 9.54
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In accordance to formerly reported failures to overexpress
the RBP2-H1-splicing variant PLU-1 (98% cDNA homology)
in various cell lines (Lu et al., 1999), in preceding experi-
ments, we also could not accomplish a significant ‘‘full-
length’’ RBP2-H1 re-expression in RBP2-H1-deficient cells
(transient and stable transfections, data not shown). Assured
by further reports indicating that PLU-1 is also a potent
transcriptional repressor (Tan et al., 2003), we assume in
accordance with other authors that overexpression of
full-length PLU-1/RBP2-H1 may not be compatible with
cellular viability at all (Lu et al., 1999). In other words, the
growth-suppressive activity of overexpressed complete RBP2-
H1 protein may even exceed the observed activities of the
C-term comprising two functional domains, the NTE1A- and
the LMO2-binding domain.
Our results demonstrate that the expressed cRBP2-H1
binds to pRb and, moreover, exerts a continuous hypophos-
phorylation at pRb Ser795 during the whole G1 phase of the
cell cycle. This functional pRb stabilization seems to be
primarily mediated by the direct interaction of the NTE1A
domain of the C-term of RBP2-H1 since a construct that lacks
this domain (nRBP2-H1), fails to show similar effects on pRb
phosphorylation. Moreover, it is important to note that direct
pRb modulation seems to be the crucial event after cRBP2-
H1 transduction, because typical cell cycle-controlling
proteins upstream of pRb were unchanged (cdk4, cyclinD1,
and p16).
In untreated A375-SM and control virus-infected A375-SM
cells, phosphorylation at Ser795 even slightly increases in
late G1. Ser795 has been described to be a phosphoacceptor
site which is implicitly required for activation of pRb
cell cycle arrest function (Connell-Crowley et al., 1997). As
a substrate of cdk4/cyclin D and cdk2/cyclin E (Connell-
Crowley et al., 1997), Ser795 is supposed to be among those
phospho-sites that undergo progressive hyperphosphorylation
from early to late G1 phase and, therefore, might be directly
involved in G1/S transition. The observation that in untreated
A375-SM cells, Ser795 is partly phosphorylated already
in early G1 – perhaps due to an additionally uncontrolled
cdk4/cyclin D activity generally discussed in melanomas
(Bachmann et al., 2004) – further reinforces the role of
cRBP2-H1 as a stabilisator of hypophosphorylated pRb, since
in cRBP2-H1-transduced cells, hypophosphorylated Ser795
was detected already in early G1, too. The exclusively cdk4-
targeted phosphoacceptor sites Ser780 and Ser807/811 lacked
to show significant differences in phosphorylation in early as
well as late G1 in cRBP2-H1-transfected cells. Therefore, we
suggest that RBP2-H1 does not act as a cdk-specific inhibitor,
but as a pRb phosphoacceptor site-specific stabilisator,
although we have not yet investigated the remaining 12 pRb
phospho-sites of pRb. A further argument in favor of this
hypothesis is that a direct interaction of retinoblastoma-
binding proteins with cdks has never been detected so far.
In addition to the cRBP2-H1-dependent cell cycle control
of pRb suggested here, other pRb-independent functions of
full-length RBP2-H1 may also contribute to transcriptional
control. Strikingly, all splicing variants of the PLU-1 gene,
that is RBP2-H1, RBBP2H1a, and PLU-1, comprise highly
conserved motifs indicating a possible role as direct trans-
cription factors, for eexample two DNA-binding zinc finger
(leukemia-associated protein) motifs, the common dri motif
(dead ringer protein, firstly described in Drosophila melano-
gaster), five nuclear localization motifs and the try/tyr/phe/cys
domain reported as potential binding site for the repressive
transcription factors, BF-1 and PAX9 (Tan et al., 2003; Roesch
et al., 2005b). Therefore, lentiviral re-establishing of these
domains in future studies could help to better understand the
full spectrum of possible tumor-suppressive and antiproli-
ferative effects of RBP2-H1.
In agreement with a broader tumor-suppressive activity of
RBP2-H1, we found a differential expression of various
melanoma-associated genes which are, only in part, directly
linked to the pRb/E2F pathway; for example bone morpho-
genetic protein 2, follistatin, and transforming growth factor
alpha (Bracken et al., 2004). Transforming growth factor
alpha, downregulated in cRBP2-H1-transduced cells, was
shown to be involved in autocrine growth of melanoma cells
(Gordon-Thomson et al., 2001). Follistatin, also downregu-
lated, inhibits activin-mediated growth reduction and apop-
tosis in melanoma cells (Stove et al., 2004). Finally, BMP-2,
upregulated in transduced cells, was shown to reduce the
secretion of HGF (Chattopadhyay et al., 2004), which
represents a potent pro-proliferative cytokine eliciting mito-
genic, motogenic, and morphogenic responses in melanoma
cells (Noonan et al., 2003). Consistent with BMP-2 upregu-
lation in cRBP2-H1-transduced cells, HGF was found to be
strongly suppressed. Thus, for all four candidates, follistatin,
transforming growth factor alpha, BMP-2, and HGF, we
found transcriptional responses typical for a more benign
melanocytic phenotype. Beside to E2F downstream target
genes, further target genes of other pRb-inhibited transcrip-
tion factors, such as SPI1 and PP-1alpha2 (not shown) (Taya,
1997), were identified by IngenuityTM.
Since neither pRb, nor E2F, SPI1, or PP-1alpha2 were
differentially expressed after transduction, the transcriptional
regulation of downstream genes might be caused by a
functional modulation of pRb and pRb-inhibited factors on
the protein level, for example due to an altered E2F/SPI1/
PP-1alpha2 release after RBP2-H1/pRb interaction. However,
common E2F-transactivated S-phase genes, such as DHFR,
TK1, DNA-polymerase alpha were not found differentially
expressed. Therefore, further, yet unknown mechanisms,
independent from pRb, might be involved, too. One example
of cRBP2-H1 activity that is probably independent of pRb is
the upregulation of TCF4 which represents another highly
melanoma-relevant pathway. Transcription factors of the
TCF family are downstream effectors of the Wnt/b-catenin-
signaling pathway which is implicated in developmental
processes and progression of some tumors, especially
colon carcinoma and melanoma (Goding, 2000; Poser and
Bosserhoff, 2004). Depending on the interaction with co-
regulative factors like b-catenin or Groucho (both not
regulated), TCF can act as transcriptional activator or repres-
sor. In absence of b-catenin, TCF represses the transcription
of several target genes, including dopachrome tautomerase
and tyrosinase-related protein 1, (Furumura et al., 2001;
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Brantjes et al., 2002). Next to tyrosinase, both dopachrome
tautomerase and tyrosinase-related protein 1, represent
major pigmentation enzymes of melanocytes (Widlund
et al., 2002). Recently, Widlund et al. (2002) suggested that
also MITF is a target gene of Wnt/b-catenin/TCF-signaling
pathway. MITF is discussed as a master gene for post-
natal melanocytic survival as well as a key transcription
factor for regulation of melanocytic differentiation (Carlson
and Faulkner, 1989; Carlson et al., 2001; Widlund et al.,
2002; Vance and Goding, 2004). Interestingly, a direct
interaction of MITF with hypophosphorylated pRb has been
postulated some years ago when Yavuzer et al. suggested
that the co-regulatory effects of MITF and pRb can lead
to melanocytic differentiation (Yavuzer et al., 1995). A
recent publication by Carreira et al. (2005) even suggested
that cooperation between MITF and pRb can induce G1 cell
cycle arrest. The finding that cRBP2-H1 transduction induces
a strong G1 arrest leads to the hypothesis that the
corresponding proteins may interact in higher-order protein
complexes.
Since the subcloned cRBP2-H1 also includes a LMO2
binding motif we further screened the regulated transcripts
(IngenuityTM and manually) to reveal or exclude possible
connections to LMO2 functions. However, no functional
linkages could be found suggesting that most of the observed
gene expression changes are due to the NTE1A.
As a possible effect of the observed changes in gene
expression, a block in G1/S transition was detected in cell
cycle profile analyses of RBP2-H1-transduced cells. This
observation and the recorded decrease in cellular prolifera-
tion support the hypothesis that RBP2-H1 exerts a tumor-
suppressive function in melanocytes. Together with previous
data on a common deficiency of RBP2-H1 in melanoma cells
(Vogt et al., 1999; Roesch et al., 2005b), this study suggests
that loss of RBP2-H1 might not only serve as a diagnostic and
prognostic marker for melanoma, but re-establishing parts of
its function in metastatic melanomas may open new avenues
of experimental strategies for cure of metastatic malignant
melanoma.
MATERIALS AND METHODS
Cell culture and retroviral transduction
The melanoma cell line A375-SM, kind gift from K. Gehlsen, SKCC,
San Diego, CA (Gehlsen et al., 1992) was taken into culture in RPMI
1640 (PAN Biotech, Aidenbach, Germany). For partial RBP2-H1
overexpression, a lentiviral construct comprising the C-term (cRBP2-
H1) with its NTE1A was cloned in cooperation with the Institute for
Medical Microbiology and Hygiene, University of Regensburg.
Briefly, HEK 293T cells were grown in DMEM (BRL/Gibco,
Karlsruhe, Germany), 4.5 g/l glucose, 10% fetal bovine serum
(PAN Biotech GmbH, Aidenbach, Germany). Cells (4 106) were
seeded per 10 cm dish 24 hours before transfection and fresh
complete DMEM medium was added to the plates prior to adding
the transfection mixture. The transfection and transduction proce-
dure was essentially carried out as described previously (Schneider-
Brachert W et al., 2004). In brief, 30 mg of each retroviral vector
pQCXIP constructs containing the C-term of RBP2-H1 (aa
1385–1580 (Vogt et al., 1999)) with the NTE1A homologue domain
(aa 1390–1490) or enhanced GFP (control subcloned from pEGFP-
N1, Clontech, Palo Alto, CA) and the packaging plasmid, pCL-10A1
(RetroMax System, Imgenex, San Diego, CA), were transfected by
calcium phosphate co-precipitation. Fresh medium was added
5 hours after transfection. Viral supernatants were harvested 24
and 48 hours later, pooled and passed through a 0.45-mm filter.
A375-SM were infected with a 1:4 dilution of virus containing
supernatant with fresh medium at a final concentration of 8mg/ml
polybrene (Sigma, Taufkirchen, Germany). After four rounds of
transduction, all obtained recombinant cell lines were selected
with 2.5 mg/ml puromycin (Sigma, Taufkirchen, Germany) to remove
uninfected cells. The selection procedure was finished after 1 week
when no viable cells remained in the appropriate control plate
containing non-transduced parental cells. The optimal puromycin
concentration which was necessary to kill the parental cell line was
determined in previous experiments using increasing doses of
puromycin (1.0–5 mg/ml). The different transduced cell lines showed
no distinct morphological differences as determined by microscopy.
Stably lentivirus-infected A375-SM cells were harvested 3 and
9 hours after synchronization with 100 nM colchicine to detect
G1-phase-specific CDK-mediated pRb phosphorylation.
For control of NTE1A-specific functionality, a construct of RBP2-
H1 (aa 1–860, nRBP2-H1) lacking the C-term and the NTE1A
domain, respectively, was subcloned into the pcDNA3.1(þ )
mammalian expression vector. A375-SM cells were transfected
using LipofectamineTM transfection reagent (Invitrogen, Karlsruhe,
Germany). Subsequently, stably transfected clones were selected
with neomycin according to standard procedures.
Western blot analysis
Protein extraction was performed using Clontech’s extraction/
labeling buffer (Clontech, Palo Alto, CA). For standard SDS-PAGE/
Western blotting, 40 mg of total protein lysate were analyzed.
Blots were incubated with anti-FLAG antibody (2.5 mg/ml, Sigma,
Deisenhofen, Germany) or antitotal pRb (Rb4H1), anti-Phospho-Rb
Ser795, anti-Phospho-Rb Ser780, anti-Phospho-Rb Ser807/811, anti-
cyclinD1 and anti-cdk4 antibodies (1:1,000 or 1:5,000, Cell
Signaling Technology/New England Biolabs GmbH, Frankfurt,
Germany) at 41C overnight. After washing with phosphate-buffered
saline/Tween 20, horseradish peroxidase-conjugated anti-rabbit or
anti-mouse antibodies were used as secondary antibodies (whole
rabbit: Cell Signaling Technology/New England Biolabs GmbH,
Frankfurt, Germany; whole mouse: Amersham Biosciences Europe
GmbH, Freiburg, Germany). For signal detection ECLTM Plus
(Amersham Biosciences) was applied. As a loading control, PDI
was visualized with the StessGen Biotechnologies anti-PDI antibody
(1:4,000, StessGen Biotechnologies, Victoria, Canada).
Co-immunoprecipitation
Stably infected A375-SM cells were cultured in 75 cm2 flasks and
harvested at subconfluence to avoid influences of intercellular
contact on pRb function. To demonstrate binding of the cRBP2-H1
expression product to pRb, co-immunoprecipitation of FLAG-tagged
cRBP2-H1 with pRb was performed with a protein A sepharose-
coupled anti-FLAG antibody (Sigma, Deisenhofen, Germany) or,
vice versa, with the anti-pRb 4H1 antibody (Cell Signaling
Technology/New England Biolabs GmbH, Frankfurt, Germany).
Since the amount of the expressed construct was very low,
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co-immunoprecipitation was performed five times with 800 mg total
protein lysate and 2mg precipitating antibody for each approach.
Thereafter, the co-precipitated proteins were reversely detected by
Western blot analysis. To avoid blurring of specific signals between
20 and 70 kDa resulting from a possible cross-detection of
precipitating antibodies with secondary antibodies of the Western
blot, isotype specific secondary antibodies were used (goat anti-
mouse IgG2a and goat anti-mouse IgG1 from SouthernBiotech,
Birmingham, AL).
Cell cycle profile and BrdU incorporation
According to the method described previously (McGahon, 1995),
propidium iodide staining for cell cycle analysis was performed with
106 cells per experiment. In brief, cells were trypsinized and washed
with phosphate-buffered saline containing 5 mM EDTA. After
incubation with 100% ethanol, RNase A was added. Subsequently,
propidium iodide was added to a final concentration of 100 mg/ml
and intercalation into chromosomal DNA was measured using FACS
(FACS-Calibur, BD, Heidelberg, Germany) in linear mode (Ahmed
et al., 1994).
BrdU incorporation into replicated DNA was measured colori-
metrically using the Cell Proliferation ELISATM from Roche Applied
Science (Mannheim, Germany). According to the recommendations,
in a 96-well plate, 1,000 cells per well were cultured for 48 hours.
Thereafter, BrdU was added and the cells were reincubated for
additional 24 hours. After fixation and denaturation, anti-BrdU-POD
immunocomplexes were detected by the subsequent substrate
reaction using a multiwell spectrophotometer at the recommended
wavelengths.
Cell proliferation analysis
To analyze cell proliferation, a starting cell number of 10,000
stably infected cells was seeded into six wells and alamarBlueTM
(Biosource, Camarillo, CA) staining was measured fluorometrically
(triplicates). The detection of metabolized, fluorescent alamarBlueTM
correlates linearly with the number of proliferating cells.
GeneChipTM microarray assay
For investigation of transcriptional responses in cRBP2-H1-
transduced A375-SM cells, gene expression was analyzed using
the AffymetrixTM human genome expression GeneChipTM U133A 2.0
(Affymetrix, Santa Clara, CA). All analyses were performed in
duplicates comparing cRBP2-H1-transduced A375-SM with GFP
control virus-infected A375-SM and untreated A375-SM cells.
Sample preparation for microarray hybridization was carried out as
described in accordance with the Affymetrix GeneChipTM Expression
Analysis Technical Manual (Hafner et al., 2005). In all, 5 mg of total
RNA purified with RNeasyTM Mini columns (Qiagen, Hilden,
Germany) according to the manufacturer’s directions, were used to
generate double-stranded cDNA and subsequently biotin-labeled
cRNA (Affymetrix One-Cycle Target Labeling Kit). The length of the
cRNA products and fragmentation was confirmed using the Agilent
2100 bioanalyzer (Agilent Technologies, Palo Alto, CA). Obtained
fragmented cRNA products (10 mg) were hybridized to the Human
Genome U133A 2.0 GeneChipTM Arrays for 16 hours at 451C.
Hybridized arrays were washed and stained using Streptavidin
Phycoerythrin conjugate (Molecular Probes, Eugene, OR) together
with biotinylated anti-streptavidin antibody (Vector Laboratories,
Burlingame, CA), and the fluorescent signals were measured with the
Affymetrix GeneChipTM Scanner 3000. Quality control of the isolated
RNA samples and sample processing were performed at a regional
German Affymetrix Service Provider and Core Facility, ‘‘KFB –
Center of Excellence for Fluorescent Bioanalysis’’ (www.kfb-regens
burg.de).
Microarray data analysis
Affymetrix GeneChipTM Operation Software (GCOS) 1.2 was used
for Single Array Analysis. A global scaling strategy was employed
by setting the average signal intensity of all arrays to a target
value of 100. After the scaling, the detectable expressed genes were
defined using P-, M-, or A-calls (according to Affymetrix algo-
rithm). We used dChip 1.3 (Li and Wong, 2001a, b) for baseline
comparisons and stringent data evaluation. We found upregu-
lated genes in cRBP2-H1-transduced A375-SM in a combined
comparison to both GFP control virus-infected A375-SM and
untreated A375-SM cells by filtering for a minimum of one present
call in at least one of the cRBP2-H1 duplicates. Respectively,
downregulated genes were found by filtering for a minimum of
one present call in both of the control virus-infected and untreated
A375-SM duplicates. In addition, a minimum 2-fold change was set
as cutoff.
To reveal functional connections between the regulated tran-
scripts, a network analysis of the pre-filtered genes was performed as
described (Raponi et al., 2004) using the IngenuityTM Pathways
Analysis online application (www.ingenuity.com, IngenuityTM
Systems, Mountain View, CA). The linking information of the
IngenuityTM analysis is extracted from literature and data bank
entries (e.g. PubMed). The significance of networking was calculated
by integrated IngenuityTM algorithms (Raponi et al., 2004). To
increase the biological significance of our data, transcripts were
only functionally networked, if both comparisons (1) cRBP2-H1
re-expression versus control virus-infected cells and (2) cRBP2-H1
re-expression versus non-infected cells showed at least a 2-fold
regulation.
Real-time RT-PCR-based array confirmation
For RNA extraction, the RNeasyTM Mini Kit (Qiagen, Hilden,
Germany) was used according to the manufacturer’s recommenda-
tions. RNAs were subjected to quality controls using the Agilent
2100 bioanalyzer (Agilent biotechnologies, Palo Alto, CA). RT-PCR
was performed using the Reverse Transcription KitTM (Promega,
Madison, WI) according to the recommended protocol. For relative
quantitation of MME-, EDN1-, TCF4-, dopachrome tautomerase-,
HAPLN1-, and HGF-transcribed RNA, TaqManTM real-time RT-PCR
(Assay on demandTM, Applied Biosystems, Darmstadt, Germany) was
performed as triplicates as described previously (Hafner et al., 2004).
Primers and probes for 18 seconds rRNA served as endogenous
controls. Relative expression ratios were calculated using a standard
curve generated with Human Reference RNA (Stratagene, La Jolla,
CA) that contains pooled RNAs from 11 different tumor cell lines
(Hafner et al., 2003).
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